A promising new biomarker that appears in patients before stomach cancer develops may help with early detection of the disease and improve patient response to therapy, according to findings in a study led by University of Arizona Health Sciences researchers. The biomarker can be detected through a simple blood test, saving time and lowering costs. Currently, stomach cancer diagnosis requires endoscopic collection of stomach tissue through a biopsy procedure, and then analysis by pathology.
The study, ‘MiR130b from Schlafen4+ MDSCs stimulates epithelial proliferation and correlates with preneoplastic changes prior to gastric cancer’, published in Gut, was led by Dr Juanita L Merchant, chief of the Division of Gastroenterology and Hepatology at the UArizona College of Medicine, Tucson, a cancer biology programme researcher at the UArizona Cancer Center and an elected member of the National Academy of Medicine.
The biomarker, MiR130b, is a microRNA (or small non-coding RNA molecule) that can play an important role in regulating gene expression, affecting disease development and progression. MiR130b can be produced by a group of immune cells called myeloid-derived suppressor cells (MDSCs), commonly associated with infections caused by Helicobacter pylori (H pylori), a bacteria associated with ulcers. These particular cell types in the stomach correlate with early, preneoplastic changes (before a tumour develops) that can lead to gastric cancer long after an H pylori infection has passed.
"Even though you get can get rid of the bacteria, oftentimes the infection itself already has initiated a cascade of events that inevitably may lead to cancer," said Dr Yana Zavros, associate head for research in the College of Medicine, Tucson's Department of Cellular and Molecular Medicine and the Cancer Center's shared resource director for Tissue Acquisition Cellular and Molecular Analysis. "That is why early detection is so important."
The study arose out of basic science mouse models that simulated changes in the stomach similar to that caused by H pylori. This led the researchers to identify MiR130b in the mouse models and the researchers also detected the same microRNA in the plasma of human patients that either had precancerous changes or those that already had progressed to cancer.
"This was a retrospective study," said Merchant, who is a member of the university's BIO5 Institute. "It is very exciting because now we can begin looking at this biomarker more prospectively in different patient populations. This molecular signature (the microRNA—MiR130b) that we discovered may help us see if patients have changes in their mucosa (the membrane that lines the stomach) related to having H pylori. And a blood sample would be less invasive and then could be a way to make the decision whether we need to bring a patient in for an endoscopy."
The researchers believe these new findings in gastric cancer may help to address why other GI cancers also are resistant to therapy. The researchers have a ‘sub-project’ in the Cancer Center's U54 grant (Partnership for Native American Cancer Prevention) to study detection of the microRNA (described in the Gut paper) in members of Native American populations with H pylori.
"The underlying mechanism by which a patient may not respond well in gastric cancer may be applicable in other organs as well," added Zavros. "The way the cells interact with each other to render that patient resistant to therapy may be quite similar between gastric, pancreatic and colon cancers."
"There may be dual-purposes. We can look at it as a biomarker to help us from a diagnostic perspective, but we also can look at therapies that can be developed based on what this microRNA itself is targeting,” said Merchant.
Another project funded by the Cancer Center's ‘Sparking Bench-to-Bedside Team Science Project’ award is building from results of this study to explore therapies for pancreatic and gastric cancer. The investigators are exploring the tumour microenvironment, in particular the immune cell MDSCs, referred to previously, that appears to dampen the chemotherapeutic response to immunotherapies.
The project relies heavily on the ‘BioDroid’ programme, established by Zavros, which develops miniature organs in the lab with a realistic microanatomy, also known as organoids. These are used in collaboration with the Tissue Acquisition Repository for Gastrointestinal and HEpaTic Systems (TARGHETS), created by Merchant. TARGHETS is a GI/Hepatology biorepository that collects samples from patients who undergo endoscopy.
Zavros and Merchant are looking to the BioDroid and TARGHETS efforts to reveal additional information that will allow them to develop new approaches to address resistance of gastric cancer to immunotherapies.
"We want to find a way to reprogram the cancer cells or the immune cells within that patient's tumour environment to make the patient more responsive to the therapy," Zavros concluded. "A biomarker gives us a place to start."
To access this paper, please click here